Toutes les études
Inscription sur invitationPHASE1, PHASE2INTERVENTIONNEL

Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy

This research study is looking at a new potential medicine, SRP-1003, for people living with Type 1 Myotonic Dystrophy (DM1). The main goals are to check if the medicine is safe and if the body tolerates it well. Scientists also want to understand how the medicine moves through the body and what effects it has. The study involves giving different doses of SRP-1003, either into a vein or under the skin, or a dummy medicine (placebo). This helps researchers compare the real medicine's effects. Participants will be carefully monitored to see how they react to the treatment. This is an early-stage study, meaning it's one of the first times this medicine is being tested in people with DM1.

En un coup d'œil

Statut
Inscription sur invitation
Phase
PHASE1, PHASE2
Sponsor
Sarepta Therapeutics, Inc.
Objectif d'inscription
78
Démarrer
04 Mar 2024
Achèvement estimé
31 Déc 2026

De quoi parle cette étude ?

This study is an important step in developing new treatments for Type 1 Myotonic Dystrophy (DM1). DM1 is a condition that affects your muscles, making them weak and sometimes making it hard for them to relax after you use them. The new medicine being tested, called SRP-1003, aims to tackle some of the problems caused by DM1.

In this study, researchers want to answer several key questions. Firstly, is SRP-1003 safe for people with DM1, and can their bodies handle it without too many side effects? Secondly, they want to understand how the medicine works in the body – for example, how much of it gets into your system and how long it stays there. Thirdly, they're hoping to see if the medicine has any positive effects on the body's processes related to DM1.

To find these answers, some people in the study will receive SRP-1003, while others will receive a 'placebo', which looks exactly like the medicine but contains no active drug. This is a common way to compare results fairly and find out if any changes are truly due to the new medicine. Because this is an early-stage study, it's about gathering initial information to guide future research.

Points clés

  • This study is testing a new medicine (SRP-1003) for Type 1 Myotonic Dystrophy.
  • It's an early-stage study focusing on safety, how the body handles the medicine, and potential effects.
  • Participants will receive either the new medicine or a dummy medicine (placebo).
  • The medicine will be given into a vein or as an injection under the skin.
  • Strict rules apply for who can and cannot join, including age and medical history.

Qui peut être éligible ?

To join this study, you need to have a confirmed diagnosis of Type 1 Myotonic Dystrophy (DM1) through a genetic test. Your doctor also needs to have noticed clear signs of DM1, including muscle stiffness (myotonia). Your DM1 symptoms must have started after you turned 12 years old, and you must be able to walk at least 10 metres on your own before the study starts. You'll need to be between 18 and 65 years old.

There are also some reasons why you might not be able to join. For example, if you have diabetes that's not well controlled, very high blood pressure that's not under control, or serious heart, liver, or kidney problems. If you have congenital DM1 (a type of DM1 that starts very early in life), or certain infections like HIV or hepatitis B or C, you wouldn't be able to participate. You also shouldn't have had a muscle biopsy in your lower leg in the last three months, or be planning to have one during the study.

If you could become pregnant or make someone pregnant, you would need to use very effective contraception throughout the study and for 90 days after your last dose. You also wouldn't be able to donate sperm or eggs during this time.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Do I have a genetically confirmed diagnosis of Type 1 Myotonic Dystrophy?
  2. Did my DM1 symptoms start after I turned 12 years old?
  3. Can I walk at least 10 meters on my own?
  4. Am I between 18 and 65 years old?
  5. Do I have any serious uncontrolled medical conditions like diabetes, high blood pressure, or heart/liver/kidney disease?
  6. Am I willing to use effective contraception if I could become pregnant or make someone pregnant?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, you'll first have screening visits to make sure you meet all the study requirements. Once enrolled, you'll either receive SRP-1003 or a placebo, which looks identical but has no active drug. The medicine will be given either into a vein (like a drip) or as an injection under the skin.

Some participants will receive a single dose, while others will receive multiple doses over time. You will have regular appointments at the study clinic for check-ups, blood tests, and other assessments to see how you are doing and how your body is responding to the treatment. These visits help the research team monitor your safety and the medicine's effects. The total length of your involvement in the study will depend on which part of the study you are in (single or multiple doses), but it will involve follow-up after your last dose. You will be told the exact schedule of visits and procedures if you are considering joining.

Risques et avantages potentiels

Participating in a clinical trial may offer potential benefits, such as gaining access to a new medicine before it's widely available and contributing to medical knowledge that could help others. However, there are also potential risks, including side effects from the study medicine, or having to spend time on clinic visits and tests. There's no guarantee that the medicine will help you personally. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (35)

  • Liverpool Hospital
    Code postal vérifié
    Liverpool, Australia
  • Sunshine Coast University Hospital
    Code postal vérifié
    Birtinya, Australia
  • Royal Brisbane And Women's Hospital
    Code postal vérifié
    Herston, Australia
  • Alfred Health
    Code postal vérifié
    Melbourne, Australie
  • Nucleus Network Brisbane Clinic
    Code postal vérifié
    Herston, Australia
  • Mater Hospital Brisbane
    Code postal vérifié
    South Brisbane, Australia
  • Universitair Ziekenhuis Gent
    Code postal vérifié
    Gand, Belgique
  • UZ Leuven
    Code postal vérifié
    Leuven, Belgium
  • University Of Calgary
    Code postal vérifié
    Calgary, Canada
  • University Of Alberta
    Code postal vérifié
    Edmonton, Canada
  • McGill University
    Code postal vérifié
    Montréal, Canada
  • University Hospital of Angers
    Code postal vérifié
    Angers, France

Questions fréquentes

What is Type 1 Myotonic Dystrophy (DM1)?

DM1 is a genetic condition that causes muscles to become weak and can affect how they relax. It can also cause problems in other parts of the body.

Que signifie 'contrôlé par placebo' ?

It means some participants will receive the active medicine, while others will receive a 'dummy' medicine (placebo) that looks the same but has no drug in it. This helps researchers compare the true effects of the new medicine.

What does 'Phase 1/2' mean for a study?

These are early stages of research. Phase 1 mainly checks if the medicine is safe and what dose can be given. Phase 2 starts looking at whether the medicine actually works for the condition, as well as continuing to check safety.

Will I know if I'm getting the active medicine or the placebo?

No, this is a 'double-blinded' study, meaning neither you nor the study team will know who is getting the active medicine and who is getting the placebo. This ensures the results are fair and unbiased.

Comment le médicament est-il administré ?

The medicine SRP-1003 will be given either into a vein (like a drip in your arm) or as an injection just under the skin.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "Study of SRP-1003 in Participants With Type 1 Myotonic Dystr… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.